About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a company based in San Carlos (United States) founded in 2000.. Eiger BioPharmaceuticals has raised $8.9 million across 7 funding rounds from investors including RA Capital, Perceptive Advisors and HBM Healthcare Investments. The company has 56 employees as of December 31, 2022. Eiger BioPharmaceuticals operates in a competitive market with competitors including Spark Therapeutics, Denali Therapeutics, AskBio, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter San Carlos, United States
- Employees 56 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$15.77 M17as on Dec 31, 2023
-
Net Profit
$-74.96 M23as on Dec 31, 2023
-
EBITDA
$-71.79 M23as on Dec 31, 2023
-
Total Equity Funding
$8.9 M (USD)
in 7 rounds
-
Latest Funding Round
$3 M (USD), Post-IPO
Apr 28, 2019
-
Investors
RA Capital
& 6 more
-
Employee Count
56
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has successfully raised a total of $8.9M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $3.0M
-
First Round
First Round
(17 Sep 2010)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2019 | Amount | Post-IPO - Eiger BioPharmaceuticals | Valuation |
investors |
|
| Mar, 2016 | Amount | Post-IPO - Eiger BioPharmaceuticals | Valuation |
investors |
|
| Nov, 2015 | Amount | Post-IPO - Eiger BioPharmaceuticals | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eiger BioPharmaceuticals
Eiger BioPharmaceuticals has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Perceptive Advisors and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Early-stage investing in IT and healthcare ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eiger BioPharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eiger BioPharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eiger Biopharmaceuticals Comparisons
Competitors of Eiger BioPharmaceuticals
Eiger BioPharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spark Therapeutics, Denali Therapeutics, AskBio, Poseida Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eiger Biopharmaceuticals
Frequently Asked Questions about Eiger BioPharmaceuticals
When was Eiger BioPharmaceuticals founded?
Eiger BioPharmaceuticals was founded in 2000 and raised its 1st funding round 10 years after it was founded.
Where is Eiger BioPharmaceuticals located?
Eiger BioPharmaceuticals is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
Is Eiger BioPharmaceuticals a funded company?
Eiger BioPharmaceuticals is a funded company, having raised a total of $8.9M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $6M, raised on Sep 17, 2010.
How many employees does Eiger BioPharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Eiger BioPharmaceuticals is 56.
What is the annual revenue of Eiger BioPharmaceuticals?
Annual revenue of Eiger BioPharmaceuticals is $15.77M as on Dec 31, 2023.
What does Eiger BioPharmaceuticals do?
Developer of antiviral agents against targets in the treatment of hepatitis. It offers a lead product candidate, avexitide a first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.
Who are the top competitors of Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals's top competitors include Spark Therapeutics, Juno Therapeutics and AskBio.
Who are Eiger BioPharmaceuticals's investors?
Eiger BioPharmaceuticals has 7 investors. Key investors include RA Capital, Perceptive Advisors, HBM Healthcare Investments, Vivo Capital, and InterWest.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.